WallStSmart

Agilent Technologies Inc (A)vsIDEXX Laboratories Inc (IDXX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Agilent Technologies Inc generates 64% more annual revenue ($7.07B vs $4.30B). IDXX leads profitability with a 24.6% profit margin vs 18.3%. A appears more attractively valued with a PEG of 1.16. IDXX earns a higher WallStSmart Score of 61/100 (C+).

A

Buy

61

out of 100

Grade: C+

Growth: 6.0Profit: 8.0Value: 7.3Quality: 5.3
Piotroski: 3/9Altman Z: 1.99

IDXX

Buy

61

out of 100

Grade: C+

Growth: 6.7Profit: 9.5Value: 4.7Quality: 5.0
Piotroski: 5/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ASignificantly Overvalued (-320.3%)

Margin of Safety

-320.3%

Fair Value

$30.67

Current Price

$111.30

$80.63 premium

UndervaluedFair: $30.67Overvalued
IDXXSignificantly Overvalued (-40.3%)

Margin of Safety

-40.3%

Fair Value

$462.49

Current Price

$577.26

$114.77 premium

UndervaluedFair: $462.49Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

A2 strengths · Avg: 8.5/10
Return on EquityProfitability
20.0%9/10

Every $100 of equity generates 20 in profit

Operating MarginProfitability
22.9%8/10

Strong operational efficiency at 22.9%

IDXX3 strengths · Avg: 9.0/10
Return on EquityProfitability
66.2%10/10

Every $100 of equity generates 66 in profit

Profit MarginProfitability
24.6%9/10

Keeps 25 of every $100 in revenue as profit

Operating MarginProfitability
29.8%8/10

Strong operational efficiency at 29.8%

Areas to Watch

A3 concerns · Avg: 3.0/10
Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-3.6%2/10

Earnings declined 3.6%

IDXX3 concerns · Avg: 2.0/10
PEG RatioValuation
4.022/10

Expensive relative to growth rate

P/E RatioValuation
44.2x2/10

Premium valuation, high expectations priced in

Price/BookValuation
28.7x2/10

Trading at 28.7x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : A

The strongest argument for A centers on Return on Equity, Operating Margin. Profitability is solid with margins at 18.3% and operating margin at 22.9%. PEG of 1.16 suggests the stock is reasonably priced for its growth.

Bull Case : IDXX

The strongest argument for IDXX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 24.6% and operating margin at 29.8%. Revenue growth of 14.3% demonstrates continued momentum.

Bear Case : A

The primary concerns for A are Altman Z-Score, Piotroski F-Score, EPS Growth.

Bear Case : IDXX

The primary concerns for IDXX are PEG Ratio, P/E Ratio, Price/Book. A P/E of 44.2x leaves little room for execution misses.

Key Dynamics to Monitor

IDXX carries more volatility with a beta of 1.70 — expect wider price swings.

IDXX is growing revenue faster at 14.3% — sustainability is the question.

IDXX generates stronger free cash flow (323M), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

A scores higher overall (61/100 vs 61/100), backed by strong 18.3% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Agilent Technologies Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Agilent Technologies, Inc. is an American analytical instrumentation development and manufacturing company that offers its products and services to markets worldwide. Its global headquarters is located in Santa Clara, California.

IDEXX Laboratories Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IDEXX Laboratories, Inc. is an American multinational corporation engaged in the development, manufacture, and distribution of products and services for the companion animal veterinary, livestock and poultry, water testing, and dairy markets.

Want to dig deeper into these stocks?